Cadenttx
Cambridge, US · 1 known investors
Cadent Therapeutics is a neuroscience company developing clinical-stage molecules for neuropsychiatric and movement disorders, including programs for schizophrenia (CAD-9303), movement disorders (CAD-1883), and treatment-resistant depression (MIJ821). Based in Cambridge, Massachusetts, the company was acquired by Novartis in an agreement announced in December 2020.
BiotechHealthtech